Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation (EVITRA)
Study to Compare Once-daily Extended Release Tacrolimus Versus Twice-daily Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce the Risk of Allosensitisation
Sponsor: Imperial College Healthcare NHS Trust
Terminated
Non-feasible due to change in clinical practice
Other terminated trials from Imperial College Healthcare NHS Trust
- Brain Tumor · Jul 2025
- Hypertension, Pulmonary · Phase NA · Jan 2019
- Chronic Obstructive Pulmonary Diseases · Phase NA · Dec 2017
- Breast Feeding · Nov 2017
- Psoriatic Arthritis · Phase NA · Sep 2017
See all terminations from Imperial College Healthcare NHS Trust
Listed as NCT03689075, this PHASE4 trial focuses on Allosensitization and Immunosuppression and remains terminated or withdrawn. Sponsored by Imperial College Healthcare NHS Trust, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE4
Status: Unknown → Terminated
-
Sep 2024 — May 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Dec 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2023 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Imperial College Healthcare NHS Trust
For direct contact, visit the study record on ClinicalTrials.gov .